Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam

被引：6

作者：

Xuan, Nguyen Thanh ^{[1
]}

Hop, Vu Quang ^{[2
]}

Kien, Truong Quy ^{[3
]}

Toan, Pham Quoc ^{[3
]}

Thang, Le Viet ^{[3
]}

Binh, Ha Thanh ^{[3
]}

Van Tran, Pham ^{[2
]}

Minh, Hoang Thi ^{[2
]}

Man, Pham Thi ^{[4
]}

Cuong, Hoang Xuan ^{[5
]}

Ben, Nguyen Huu ^{[5
]}

Phuong, Nguyen Minh ^{[5
]}

Linh, Nguyen Tung ^{[5
]}

Linh, Nguyen Thuy ^{[6
,7
]}

Dung, Vu Dinh ^{[6
]}

Quyen, Le Thi Bao ^{[8
]}

Hang, Dinh Thi Thu ^{[8
]}

Su, Hoang Xuan ^{[8
,9
]}

机构：

[1] Vietnam Mil Med Univ, Mil Hosp 103, Dept Internal Med, Hanoi, Vietnam

[2] Vietnam Mil Med Univ, Mil Hosp 103, Dept Clin Biochem, Hanoi, Vietnam

[3] Vietnam Mil Med Univ, Mil Hosp 103, Dept Nephrol & Dialysis, Hanoi, Vietnam

[4] Natl Hosp Dermatol & Venereol, Dept Pharm, Hanoi, Vietnam

[5] Vietnam Mil Med Univ, Dept Occupat Med, Hanoi, Vietnam

[6] Vietnam Mil Med Univ, Inst Biomed & Pharm, Hanoi, Vietnam

[7] Natl Univ Hanoi, Fac Biol, Hanoi, Vietnam

[8] Hanoi Univ Sci & Technol, Hanoi, Vietnam

[9] Vietnam Mil Med Univ, Inst Biomed & Pharm, 222 Phung Hung str, Hanoi 100000, Vietnam

来源：

TRANSPLANTATION PROCEEDINGS | 2022年 / 54卷 / 08期

关键词：

GENETIC-POLYMORPHISM; PHARMACOKINETICS; GENOTYPE;

D O I：

10.1016/j.transproceed.2022.07.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. This study aims to investigate the frequencies and association of CYP3A5 poly-morphism with tacrolimus concentration among renal transplant recipients in Vietnam. Methods. Sixty-eight kidney transplant recipients were included in this study from the department of nephrology and dialysis, Military Hospital 103. Blood samples were collected for monitoring of tacrolimus levels and determination of CYP3A5 genetic polymorphism.Results. A total of 68 patients studied. The CYP3A5*3*3, CYP3A5*1*3, and CYP3A5*1*1 genotypes were detected in 48 (70.6%), 16 (23.5%), and 4 (5.9%), respectively. Tacrolimus con-centrations were much lower in CYP3A5 expressors than in CYP3A5 nonexpressors on the first day, month 1, 3, 6, and 12 (5.98 +/- 1.05 vs 6.57 +/- 1.03,P= .03; 5.79 +/- 1.13 vs 6.82 +/- 1.05, P < .001; 4.76 +/- 1.48 vs 6.73 +/- 1.09, P < .001; 4.29 +/- 1.64 vs 6.46 +/- 1.23, P < .001; 4.20 +/- 1.36 vs 6.04 +/- 1.26, P < .001), respectively. Notably, the concentration/dose ratio in the CYP3A5 expressors was lower than in CYP3A5 nonexpressors at time points of follow up (P < .001). However, there were no significant differences in the age, sex, HLA mismatch, type of donors, acute rejection, and creatinine levels at time points between group of CYP3A5 expres-sors and those of CYP3A5 nonexpressors.Conclusion. In conclusion, this research indicated the significant association of CYP3A5 genetic polymorphism with daily dose and tacrolimus concentrations in renal transplant recipi-ents. This study provided a closer step to individualize the dose of tacrolimus in renal transplant patients in Vietnam.

引用

页码：2140 / 2146

页数：7

共 23 条

[1]

Baker RJ, 2019, MED BALTI MORE, V47, P625

[2] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing [J].

Birdwell, K. A. ;

Decker, B. ;

Barbarino, J. M. ;

Peterson, J. F. ;

Stein, C. M. ;

Sadee, W. ;

Wang, D. ;

Vinks, A. A. ;

He, Y. ;

Swen, J. J. ;

Leeder, J. S. ;

van Schaik, R. H. N. ;

Thummel, K. E. ;

Klein, T. E. ;

Caudle, K. E. ;

MacPhee, I. A. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :19-24

[3] Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus [J].

Chen, J. S. ;

Li, L. S. ;

Cheng, D. R. ;

Ji, S. M. ;

Sun, Q. Q. ;

Cheng, Z. ;

Wen, J. Q. ;

Sha, G. Z. ;

Liu, Z. H. .

TRANSPLANTATION PROCEEDINGS, 2009, 41 (05) :1557-1561

[4] Impact of Cytochrome P450 3A and ATP-Binding Cassette Subfamily B Member 1 Polymorphisms on Tacrolimus Dose-Adjusted Trough Concentrations Among Korean Renal Transplant Recipients [J].

Cho, J. -H. ;

Yoon, Y. -D. ;

Park, J. -Y. ;

Song, E. -J. ;

Choi, J. -Y. ;

Yoon, S. -H. ;

Park, S. -H. ;

Kim, Y. -L. ;

Kim, C. -D. .

TRANSPLANTATION PROCEEDINGS, 2012, 44 (01) :109-114

[5] KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients [J].

Eckardt, Kai-Uwe ;

Kasiske, Bertram L. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 :S1-S155

[6] Immunosuppressive drugs for kidney transplantation [J].

Halloran, PF .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (26) :2715-2729

[7] CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients [J].

Htun, Y. Y. ;

Swe, H. K. ;

Saw, T. M. .

TRANSPLANTATION PROCEEDINGS, 2018, 50 (04) :1034-1040

[8] Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].

Kuehl, P ;

Zhang, J ;

Lin, Y ;

Lamba, J ;

Assem, M ;

Schuetz, J ;

Watkins, PB ;

Daly, A ;

Wrighton, SA ;

Hall, SD ;

Maurel, P ;

Relling, M ;

Brimer, C ;

Yasuda, K ;

Venkataramanan, R ;

Strom, S ;

Thummel, K ;

Boguski, MS ;

Schuetz, E .

NATURE GENETICS, 2001, 27 (04) :383-391

[9] Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients [J].

Largeau, Berenger ;

Barin-Le Guellec, Chantal ;

Longuet, Helene ;

Lesne, Philippe ;

Bouvarel, Antoine ;

Preteseille, Laura ;

Marquet, Pierre ;

Halimi, Jean-Michel ;

Buchler, Matthias ;

Gatault, Philippe ;

Noble, Johan .

PROGRESS IN TRANSPLANTATION, 2019, 29 (04) :300-308

[10] Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients [J].

Mac Guad, R. ;

Zaharan, N. L. ;

Chik, Z. ;

Mohamed, Z. ;

Peng, N. K. ;

Adnan, W. A. H. W. M. .

TRANSPLANTATION PROCEEDINGS, 2016, 48 (01) :81-87

← 1 2 3 →